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Abstract
Background & Aims
The extent of entry of multidrug-resistant Escherichia coli from the community into the hospi-
tal and subsequent clonal spread amongst patients is unclear. To investigate the extent and
direction of clonal spread of these bacteria within a large teaching hospital, we prospectively
genotyped multidrug-resistant E. coli obtained from community- and hospital associated
patient groups and compared the distribution of diverse genetic markers.
Methods
A total of 222 E. coli, classified as multi-drug resistant according to national guidelines, were
retrieved from both screening (n = 184) and non-screening clinical cultures (n = 38) from
outpatients and patients hospitalized for various periods. All isolates were routinely geno-
typed using an amplified fragment length polymorphism (AFLP) assay and real-time PCR
for CTX-M genes. Multi-locus sequence typing was additionally performed to confirm clus-
ters. Based on demographics, patients were categorized into two groups: patients that were
not hospitalized or less than 72 hours at time of strain isolation (group I) and patients that
were hospitalized for at least 72 hours (group II).
Results
Genotyping showed that most multi-drug resistant E. coli either had unique AFLP profiles or
grouped in small clusters of maximally 8 isolates. We identified one large ST131 clade com-
prising 31% of all isolates, containing several AFLP clusters with similar profiles. Although
different AFLP clusters were found in the two patient groups, overall genetic heterogeneity
was similar (35% vs 28% of isolates containing unique AFLP profiles, respectively). In addi-
tion, similar distributions of CTX-M groups, including CTX-M 15 (40% and 44% of isolates in
group I and II, respectively) and ST131 (32% and 30% of isolates, respectively) were found.
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Conclusion
We conclude that multi-drug resistant E. coli from the CTX-M 15 associated lineage ST131
are widespread amongst both community- and hospital associated patient groups, with sim-
ilar genetic diversity and similar distributions of genetic markers.
Introduction
Multidrug-resistant Enterobacteriaceae, including Escherichia coli, are detected at an increas-
ingly alarming rate throughout the world [1–3]. The increasing resistance of E. coli is mainly
attributed to the pandemic spread of plasmids harbouring CTX-M cefotaximases, conferring
resistance to both beta-lactam antibiotics and other antibiotic groups, including fluoroquino-
lones and aminoglycosides [4–7]. In addition, many multi-drug resistant E. coli are also associ-
ated with significant pathogenic potential, causing a wide range of infections such as the
isolates belonging to the emerging ST131 clonal complex [8]. Together with a rapidly declining
pipeline of new antibiotics, this emergence of multi-drug resistant, pathogenic E. coli raises
serious concerns about patient and public health [9–11].
In this context, European and national guidelines [12] now recommend to screen for multi-
drug resistant micro-organisms (MDROs) including E. coli. Although screening has been dem-
onstrated to effectively control hospital-associated outbreaks [13–15], the optimal strategy for
control of multi-drug resistant Enterobacteriaceae in non-outbreak settings remains under
debate [3, 16–19].
One important factor that might hamper the effectiveness of screening and transmission
control of multi-drug resistant Enterobacteriaceae is their apparent different molecular epide-
miology compared to other MDROs. While MDROs such as vancomycin-resistant Enterococci
[20, 21] and carbapenem-resistant Pseudomonas [22–24] are typically associated with hospital
outbreaks, Enterobacteriaceae appear to be mainly community acquired and enter the hospital
from the community [25]. For instance, it was recently demonstrated that almost half of all
extended spectrum beta-lactamase (ESBL) producing E. coli were already detected in patients
at admission [3] and both the prevalent CTX-M 15 and the ST131 clonal complex are widely
detected in both the hospital and community [4–8]. However, the extent of clonal spread of
multi-drug resistant E. coli, and the extent to which this pathogen is acquired within the com-
munity or in the hospital remains unclear. More insight into these matters is essential to opti-
mize strategies for management and control of this serious threat to public health.
Active screening for MDROs, including multi-drug resistant E. coli, has been recently
implemented by our laboratory following several outbreaks with MDROs in our and other
Dutch hospitals [26–28]. In agreement with current national guidelines, all E. coli identified in
our laboratory that are resistant to multiple antibiotic groups and/ or are confirmed to produce
ESBL are labelled as MDRO and appropriate transmission control measures are undertaken. In
addition, various patient groups at high risk of acquiring MDROs, such as intensive care unit
patients and patients hospitalized for more than one week, are actively screened for MDROs
using both selective cultures and rapid molecular screening [12, 29].
In this study, multi-drug resistant E. coli identified in our laboratory were genotyped using
an in-house amplified fragment length polymorphism (AFLP) assay, which has a high discrim-
inatory power as previously validated in outbreaks with other Enterobacteriaceae [30, 31].
Results were confirmed using real-time PCR for CTX-M groups and multi-locus sequence typ-
ing (MLST). Our aims were to investigate the extent and direction of clonal spread of these
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organisms amongst our patients. Genotyping results were compared between patients that
were more likely to carry community-associated isolates and those that were more likely to
have acquired hospital-associated isolates.
Material and Methods
Ethics statement
All bacterial isolates used in this study were obtained from cultures that were taken in the con-
text of routine patient surveillance, in accordance with national guidelines [12], or in the con-
text of routine diagnostics. Since no extra action or sampling was requested other than the
medically intended and only patients were included that did not opt-out for further use of cul-
tures for scientific research, written informed consent was not obtained and no ethical approval
was required in conformity to the codes of conduct for responsible use and health research, for-
mulated in agreement with national law by the Federation of Dutch Medical Scientific Societies
(Federa) [32] [33]. PMdR coded all bacterial isolates and basic demographic data of patients
and only qualified physicians of the department of Medical Microbiology (PMdR and JMO)
had access to the original patient data. This procedure was approved and the acquisition of
additional written consent was waived specifically for this study by the Medical Ethics Com-
mittee of the Maasstad Hospital Rotterdam.
Patients
During the study period from April 1st until September 1th 2013, the first isolated multi-drug
resistant Escherichia coli from 222 patients was included in this study. For all patients basic
parameters including age, gender and postal zone were recorded. In addition, the number of
hospitalizations during the previous year, the hospitalization status and location at time of
strain isolation was documented. The number of days between admittance and strain isolation
for all hospitalized patients was documented. Based on this, patients were divided into two
groups: group I patients were either not hospitalized or hospitalized less than 72 hours at time
of strain isolation while group II patients were hospitalized for at least 72 hours at time of strain
isolation. The cut-off of 72 hours was chosen in line with other recent studies [3, 17] as not to
overestimate the number of hospital-acquired isolates [18, 34].
Cultures
In agreement with national guidelines [12], diverse patient groups in our hospital at high risk
of acquiring multi-drug resistant micro-organisms (MDROs), such as patients admitted to the
intensive-care unit and patients hospitalized for at least one week irrespective of ward, were
screened weekly with throat- and rectal swabs for MDRO carriage. In addition, some patient
groups at high risk of MDRO carriage, including patients with hospitalization in the past 6
months abroad, were screened once at admittance or in the outpatient setting. MDROs in all
these screening cultures were identified using both rapid molecular screening [12, 29] and
incubation in selective broth (see section ‘Bacterial isolates‘ below).
In addition to isolates obtained from screening cultures, all isolates from (non-screening)
clinical cultures identified as multi-drug resistant based on routine susceptibility testing using
the VITEK1 2 system (bioMérieux) were also included in this study. The majority of 184 out
of 222 isolates (83%) was obtained from screening cultures. These screening cultures were
mainly rectal swabs, with the exception of 7 throat cultures, 7 urine cultures and 3 drain cul-
tures. The remaining 38 (17%) non-screening, clinical cultures containing multi-drug resistant
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(MDR) E. coli were mainly obtained from urine, with the exception of three wound cultures,
one broncheo-alveolar lavage and one blood culture.
Bacterial isolates
MDR isolates from screening cultures were obtained after incubation of swab material in selec-
tive broth containing ceftazidime, cefotaxime, and the combinations gentamycin/ ciprofloxacin
and tobramycin/ ciprofloxacin. Isolates growing in these broths were plated on ESBL CHRO-
Magar™ or gentamycin/ ciprofloxacin or tobramycin/ ciprofloxacin plates, respectively. Anti-
microbial resistance and ESBL production of isolates growing on these plates were confirmed
with respectively VITEK1 2 susceptibility testing and disk diffusion assays. Multi-drug resis-
tance of E. coli was defined as resistance to aminoglycosides (gentamycin and/or tobramycin)
and quinolones (ciprofloxacin) and/or extended-spectrum beta-lactamase (ESBL) production
confirmed with disk diffusion assays [12] (Oxoid, Thermo Scientific).
MDR isolates from (non-screening) clinical cultures were directly identified based on
VITEK1 2 susceptibility testing. Additional disk diffusion assays to confirm ESBL production
were performed in case of resistance to ceftazidime and cefotaxime. Antimicrobial susceptibil-
ity for E. coli in the VITEK1 2 system was determined using card AST-N199 (bioMérieux).
Genotyping of MDR E. coli
All MDR E. coli were genotyped using an in-house amplified fragment length polymorphism
assay, as previously described [31]. In short, DNA was extracted from isolates using the Sigma
GenElute™ Bacterial genomic DNA kit (Sigma-Aldrich Co.) according to the manufacturer’s
protocol. The restriction-ligation reaction was performed with enzymes EcoRI, PstI, XbaI, and
NheI (Roche Molecular Biochemicals) and adaptor oligonucleotides for 2–3 hours at 37 0C.
DNA fragments were precipitated and then amplified with primers complementary to the
adaptors ligated to EcoRI and NheI sites; peco-T and pn. These primers were chosen based on
the resolution of banding patterns produced by this primer combination for E. coli strains
(data not shown). Banding patterns were visualized by agarose gel electrophoresis and gel
images were made using the Auto Chemi Imaging System (UVP, LLC). Images were analyzed
using Bionumerics software version 7 (Applied Maths, Sint-Martens-Latem, Belgium). Band-
ing patterns were compared using a densitometric curve-based method that evaluates the
intensity as well as the position of the bands to generate pairwise similarity scores (Pearson
coefficient) that were used for cluster analysis. Cluster analysis was performed by constructing
dendrograms using the unweighted pair-group method and the arithmetic mean method of
tree-building. A similarity score of at least 85% was used as cut-off for designating clusters of
similar isolates, where one band difference between patterns was allowed.
MLST was performed on all isolates according to [35], using internal fragments of the fol-
lowing seven house-keeping genes: adk (adenylate kinase), fumC (fumarate hydratase), gyrB
(DNA gyrase), icd (isocitrate/isopropylmalate dehydrogenase),mdh (malate dehydrogenase),
purA (adenylosuccinate dehydrogenase), and recA (ATP/GTP binding motif). Sequence types
were assigned by submission of the sequences to the E. coli database (available at http://mlst.
warwick.ac.uk/mlst/dbs/Ecoli).
The CTX-M genotype of all isolates was determined using a recently described, multiplex
real-time -PCR specific for the 5 major groups of CTX-M enzymes [29]. Further identification
of CTX-M genes was done by Sanger sequencing on a ABI3500 DNA analyzer of a PCR ampli-
con obtained with primers F:5’-GGGTGAAGTAAGTGACCAGAATCA-3’, and R:5’-CACGT
CAATGGGACGATGTC-3’.
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Data analysis and statistics
All patient data and data obtained from AFLP cluster analysis, CTX-M PCR results and
VITEK1 2 antimicrobial susceptibility tests were processed and analysed in Microsoft Excel
version 2010. Additional statistics were calculated using Graphpad Prism version 5.01 (Graph-
pad Inc. La Jolla, CA, USA).
Results
Characteristics of MDR E. coli isolates
During the period between April and September 2013 a total of 2401 E. coli isolates was identi-
fied, including 280 isolates (12%) isolated from 222 patients that were classified as MDRO.
Only the first isolate of each of 222 patients was included for analysis. One-hundred and fifty-
seven of 222 isolates (71%) were confirmed to produce ESBL using disk diffusion, with or with-
out additional resistance to aminoglycosides and quinolones. The other 65 isolates (29%) were
resistant to aminoglycosides and quinolones but did not produce an ESBL.
Genotyping results of MDR E. coli
All isolates were submitted to AFLP genotyping. Amongst the 222 isolates, 47 unique AFLP
profiles were found, next to 35 clusters of 2 to 8 isolates and one large cluster of 50 isolates with
similar profiles (Table 1). Additional MLST identified all isolates in the large cluster as the
ESBL-associated widespread ST131. Some of the neighbouring clusters with related AFLP pro-
file also contained ST131 isolates. In total 68 isolates (31%) were identified as ST131 (Table 2).
Other sequence types that were found in the smaller clusters were ST10, 23, 38, 73, 155, and
405. Finally, in 129 out of the 222 isolates a CTX-M gene was found, of which 93 isolates (42%)
contained CTX-M group I, which includes CTX-M 15 (Table 2). Most other CTX-M genes
belonged to CTX-M group IV (13%), which includes CTX-M 14.
A similar, heterogeneous range of different AFLP profiles was found amongst isolates from
both screening and non-screening cultures (data not shown). Notably, 45 out of the 68 isolates
Table 1. AFLP genotyping results of MDR E. coli in patient groups.
Cluster size1 All isolates (n = 222) Group I (n = 127) Group II (n = 95)
no. of
clusters
proportion of all
isolates
no. of
clusters
proportion of Group I
isolates
no. of
clusters
proportion of Group II
isolates
1 (unique proﬁle) 47 21,2% 44 34,6% 27 28,4%
2 13 11,7% 9 14,2% 13 27,4%
3 9 12,2% 4 9,4% 3 9,5%
4 2 3,6% 1 3,1% 3 12,6%
5 3 6,8% 3 11,8% - -
6 2 5,4% - - - -
7 3 9,4% 1 5,5% - -
8 2 7,2% - - - -
>10 1 (50) 22,5% 1 (27) 21,3% 1 (21) 22,1%
Total no. of different
clusters
92 100,0% 63 100,0% 47 100,0%
1Number of isolates per cluster with identical AFLP proﬁles is indicated. Proﬁles with a similarity score of at least 85%, allowing maximally one different
band (Fig 1), were considered as identical.
doi:10.1371/journal.pone.0150420.t001
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(66%) identified as ST131 were obtained from rectal screening cultures, indicating intestinal
colonization by this clonal group within our patient population.
In general, antimicrobial resistance rates were similar between the two largest CTX-M
groups, with the exception of a higher resistance rate to fluoroquinolones in CTX-M group I
(75% vs 61%, respectively; S1 Table). Amongst ST131 isolates, resistance rates against third
generation cephalosporins and fluoroquinolones were higher compared to non-ST131 isolates
(76% vs 65% and 77% vs 64%, respectively; S2 Table).
Definition and characteristics of patient groups with MDR E. coli
To compare genotyping results between patients that more likely carried community-associ-
ated isolates and patients that were more likely to have acquired a hospital-associated isolate,
we divided all patients in two groups based on hospitalisation status and, in case of hospitaliza-
tion, the number of days between admittance and strain isolation. Fifty-nine out of the 222
MDR E. coli positive patients (27%), mostly outpatients and nursing home residents, were not
hospitalized at the time of strain isolation. Amongst the 163 hospitalized patients (73%) the
number of days between hospital admission and isolation of the first MDR E. coli ranged from
0 to 86 days (median 6 days, interquartile range (IQR) 1–10 days). In total, 127 patients (57%)
were either not hospitalized or hospitalized less than 72 hours at time of strain isolation (group
I, community associated), while 95 patients (43%) were hospitalized at least 72 hours at time of
the first strain isolation (group II, hospital associated).
None of the hospitalized patients in group II were known to have a culture positive for
MDR E. coli in the last 6 months prior to hospital admission. Age and sex distribution were
similar for both groups (Table 3), as was postal code distribution (data not shown). We did not
observe a relative overrepresentation of any clinical ward amongst hospitalized patients carry-
ing MDR E. coli (data not shown).
Susceptibilities and genotyping results of MDR E. coli in the community
associated patient group
Of the 127 MDR E. coli in the community-associated patient group I, antimicrobial susceptibil-
ity data were available for 117 isolates (Table 4). Of these 117 isolates, 75 isolates (64%) were
resistant for ceftazidim and cefotaxim indicating ESBL production. ESBL production was con-
firmed with disk diffusion for 72 isolates. Plasmid encoded CTX-M enzymes were found in 69
ESBL positive- and in 2 phenotypically ESBL negative isolates. We did not detect a CTX-M
enzyme in 3 isolates confirmed to produce ESBL, suggesting the presence of another β-lacta-
mase for which we did not screen.
Sixty-three isolates (54%), of which 32 isolates produced ESBL were resistant to aminogly-
cosides, while 88 isolates (75%), of which 53 isolates produced ESBL, were resistant to
Table 2. Distribution of sequence types and CTX-M plasmids in MDR E. coli.
Genetic marker All isolates (n = 222) Group I (n = 127) Group II (n = 95)
ST131 present 68 (31%) 40 (32%) 28 (30%)
CTX-M present, total 129 (58%) 71 (56%) 58 (61%)
CTX-M group I 93 (42%) 51 (40%) 42 (44%)
CTX-M group II 6 (3%) 0 6 (6%)
CTX-M group III + V 2 (1%) 1 (1%) 1 (1%)
CTX-M group IV 28 (13%) 19 (15%) 9 (10%)
no CTX-M group 93 (42%) 56 (44%) 37 (39%)
doi:10.1371/journal.pone.0150420.t002
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quinolones (Table 4, S1 Table). Thus, ESBL production is not a prerequisite for resistance to
non β-lactam antibiotic groups.
AFLP genotyping of isolates in this patient group showed that 44 out of 127 isolates (35%)
had an unique profile when>85% similarity was considered as a single strain type (Fig 1A,
Table 1). The other 83 isolates (65%) grouped in 19 clusters with a range of 2–27 isolates per
cluster. All 27 isolates within the largest cluster were identified as ST131, next to 7 and 2 other
ST131 isolates amongst neighbouring clusters with related AFLP profiles. In total 40 ST131 iso-
lates were identified in this patient group. CTX-M group I, which includes CTX-M15, was the
most abundant amongst all isolates, being found in respectively 22 isolates (Table 2). Sixteen of
these isolates were identified as ST131. Loss of plasmid would expectedly revert the susceptibil-
ity of 17 of 22 isolates to the 3d generation cephalosporins.
Susceptibilities and genotyping results of MDR E. coli in the hospital
associated patient group
Of the 95 MDR E. coli isolates in the community-associated patient group II, antimicrobial sus-
ceptibility data was available for 91 isolates. Sixty-seven (74%) of these isolates were resistant to
ceftazidim and cefotaxim, indicative of ESBL production, which was confirmed for 66 isolates.
Plasmid encoded CTX-M enzymes were shown present in 57 ESBL positive isolates and one
ESBL negative isolate. We did not detect a CTX-M enzyme in 9 isolates with confirmed ESBL
production.
Table 3. Basic parameters of included patients.
Parameter Total Group I1 Group II2
No of patients/isolates, n 222 127 95
Median age (IQR) 66 (52–77) 62 (43–77) 69 (58–78)
Male sex, n (%) 131 (59%) 70 (55%) 57 (60%)
Median days until pos. culture (IQR)3 6 (1–10) 0 (0–1) 9 (5–11)
Median no. of past hospitalizations (IQR)4 0 (0–2) 0 (0–1) 1 (0–2)
1Group I includes isolates obtained from either non-hospitalized patients or from patients within 72 hours of
hospital admission.
2Group II includes isolates obtained from patients after 72 hours of hospital admission.
3Days until positive culture was deﬁned as the number of days between date of admittance and the date of
strain isolation. Cases of no hospitalization or isolation at the date of admittance were deﬁned as 0 days.
4The number of hospitalizations in the last year, excluding any current hospitalization, were documented.
Hospitalization was deﬁned as a stay of at least 24 hours in any hospital-associated location. Only data on
hospitalizations in our hospital were available.
doi:10.1371/journal.pone.0150420.t003
Table 4. Antimicrobial resistance rates of MDR E. coli.
Antibiotic class Total of resistant isolates (n = 208)1 Resistant isolates group I (n = 117) Resistant isolates group II (n = 91)
Any beta-lactam 204 (96%) 114 (97%) 90 (99%)
3d generation cephalosporins 142 (68%) 75 (64%) 67 (74%)
Quinolones 142 (68%) 88 (75%) 54 (59%)
Trimethoprim/ sulphonamides 115 (55%) 64 (55%) 50 (55%)
Aminoglycosides 96 (46%) 63 (54%) 33 (36%)
1 Antimicrobial susceptibility data was available for 208 out of the 222 isolates included in this study.
doi:10.1371/journal.pone.0150420.t004
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Resistance to other antibiotic classes was lower in this patient group compared to the com-
munity-associated group I: 33 isolates (36%) were resistant to aminoglycosides, of which 16
were confirmed to produce ESBL, while 54 isolates (59%) were resistant to quinolones, of
which 33 isolates were confirmed to produce ESBL (Table 4).
Genotyping of isolates in this patient group showed that 27 out of 95 isolates (28%) had an
unique AFLP profile when>85% similarity was considered as a single strain type (Fig 1B,
Table 1). The remaining 68 isolates (72%) were grouped in 20 clusters with a range of 2–21 iso-
lates per cluster. All 21 isolates within the largest cluster were identified as ST131. Together
with 7 ST131 isolates in neighbouring clusters, a total of 28 ST131 isolates was found in this
patient group. The large ST131 cluster contained both isolates with and without beta-lactamase
encoded by one of the CTX-M enzymes, with CTX-M15 being detected in respectively 14 iso-
lates, and CTX-M22 in one isolate. Loss of plasmid would expectedly revert the susceptibility
of 12 out of 14 isolates to antibiotic sensitive.
In 5 clusters within this patient group (median of 2 patients per cluster) identical AFLP pro-
files were isolated from different patients who shared the same ward at overlapping hospitaliza-
tion periods. Although in 3 of these clusters identical profiles were also isolated from
Fig 1. Genotyping of multi-drug resistant E. coli. Cluster analysis based on AFLP data with (A) similarity
matrix of community associated isolates (group I) and (B) hospital associated isolates (group II). AFLP
clusters are indicated by dark boxes, whites are unique profiles. The green bar adjacent to the similarity
matrix indicates Sequence Type 131, color-coded boxes to the left of this indicate clusters with identical
AFLP profiles.
doi:10.1371/journal.pone.0150420.g001
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demographically unrelated patients, this suggests that limited transmission of MDR E. coli
might occur within the hospital.
Comparison of genotyping results between patient groups
The percentages of isolates in group I and II containing unique ALFP profiles were respectively
35% and 28%, and both patient groups contained one large, related AFLP cluster comprising
27 and 21 isolates, respectively (Table 1). All isolates within these large AFLP clusters were part
of the larger ST131 clade. Almost all other AFLP clusters in both patient groups were unrelated.
The relative number of identified ST131 isolates was similar in both patient groups with respec-
tively 32% and 30% (Table 2). Finally, CTX-M group I plasmids, including CTX-M 15, were
the most abundant in both patient groups with 40 and 44% of isolates containing this plasmid,
respectively. Altogether, these data indicate a similar distribution of genetic markers in both
patient groups.
Discussion
Our aims were to investigate the extent and direction of clonal spread of MDR E. coli amongst
the heterogeneous patient population within our hospital. Genotyping showed that most
multi-drug resistant E. coli either had unique AFLP profiles or grouped in small clusters of
maximally 8 isolates. We identified one large ST131 clade comprising 33% of all isolates, which
contained several AFLP clusters with similar profiles.
The large AFLP clusters in both patient groups were identical in their AFLP profiles while
other clusters (but one) differed between patient groups, reflecting the high genetic diversity of
E. coli. The genetic heterogeneity of multi-drug resistant E. coli found in this study, isolated
both in hospitals and the community, is in line with an abundance of previous studies [6, 36–
41]. This heterogeneity contrasts with other multi-drug resistant organisms that are mostly
dominated by specific hospital-associated clones [20, 21, 26, 27].
Although genetic heterogeneity was slightly higher in the community-associated patient
group (35% vs. 28% of isolates containing unique ALFP profiles in group I and II, respectively),
the distribution of CTX-M plasmids was similar in both groups with CTX-M group I, includ-
ing the endemic community-associated CTX-M 15 [5, 6, 38], being the most prevalent (40% vs.
44% of isolates in group I and II, respectively). These findings are in line with other recent data
demonstrating similar distributions of CTX-M plasmids between community- and hospital-
onset infections with ESBL E. coli [42]. In addition, the distribution of the CTX-M-15 associ-
ated ST131 lineage was also similar in both patient groups. Altogether, these results suggest
that MDR E. coli are mostly acquired in the community and are not replaced by hospital-asso-
ciated clones in hospitalized patients.
The large, community-associated cluster of mainly ST131 E. coli identified in this study fur-
ther implicates the emergence of this clonal group amongst clinical isolates [8]. Emergence of
particular clonal lineages has recently also been observed for multi-drug resistant Klebsiella
pneumoniae [26] and E. coli in a specific patient population under antibiotic pressure [43].
Alternatively, the large cluster that we identified might reflect the distribution of genetic pro-
files of E. coli within our local population. The proportions of clusters and unique banding pat-
terns that we found appears to be similar to those found for E. coli in the general environment
[36].
Considering the high discriminatory power of AFLP [30, 31] and confirmation of results
with CTX-M group analysis and MLST, we did not include additional molecular typing such as
detailed sequence analysis of CTX-M, fimH, gyrA or parC in this study for further confirma-
tion. In fact, AFLP analysis has a very high concordance with phylogenetic assignation e.g.
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based on gyrA sequence typing [30]. Nonetheless, additional typing will be an interesting addi-
tion to future studies to further explore the distribution of particular subclones of E. coli within
patient groups, such as the H30 subclone of ST131, and their association with particular anti-
microbial resistance patterns [44].
In the current study, the included screening cultures mainly consisted of rectal swabs,
obtained from a pre-defined selection of patients within our hospital. Although other patient
characteristics such as underlying disease and hospital ward of admission were heterogeneous,
we cannot rule out that the above mentioned selection might bias the distribution of genetic
markers found amongst isolates. However, AFLP profiles of the 38 non-screening cultures, all
from extra-intestinal origin, did not form a separate cluster but randomly clustered together
with E. coli from intestinal origin. Therefore, we currently do not have an indication of bias
within our data. Nonetheless, future studies should non-selectively screen for MDR E.coli in all
patients at multiple anatomical sites (e.g intestinal and urine) over a longer period.
The cut-off of 72 hours to define community- and hospital-associated patient groups was
chosen in line with other recent studies [3, 17] as not to overestimate the number of hospital-
acquired infections [18, 34]. This cut-off remains somewhat arbitrary as we did not screen all
patients at admission for MDR E. coli. Therefore, we cannot say whether isolates are truly com-
munity- or hospital acquired. Yet in a small subset of 24 patients in the hospital-associated
group with earlier negative screening cultures for MDR E. coli during the same admission sug-
gesting true hospital acquired isolates, separate genotyping identified 12 unique profiles (50%)
and 6 clusters of 2 isolates (50%) (data not shown). These findings further support our results
suggesting that hospitalized patients do not acquire a specific hospital-associated clone.
Within our hospital, isolated MDROs are routinely genotyped to enable recognition of
potential transmission among patients. We observed limited transmission of identical AFLP
profiles of MDR E. coli between hospitalized patients sharing the same ward at overlapping
hospitalization periods. However, we did not fully sequence CTX-M plasmids and therefore
cannot confirm whether transmission of plasmids occurred between isolates of different
patients. Yet in the absence of a clear hospital-associated outbreak situation and given our
results that most MDR E. coli are likely acquired in the community, it remains debatable
whether this required labour for monitoring is justified in the daily diagnostics laboratory.
Although for many Enterobacteriacea routine genotyping has proven to be very useful, in
view of our findings the monitoring of potentially emerging, clinically significant clones of
MDR E.coli seems less meaningful. Further studies including routine screening of all patients
at admittance, more detailed documentation of demographics and sequencing of plasmids are
required to determine the true transmission rate and effectiveness of screening and transmis-
sion control for MDR E. coli.
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